BMI-1 and survivin expression with clinicopathological correlation and prognostic impact in B and T/NK- cell non-Hodgkin lymphoma

Abstract

Background: The pathogenesis of non-Hodgkin lymphoma is a complex process that involves several molecular changes. Alterations in polycomb group proteins as well as Survivin have been described but details are still lacking particularly in T/NK-cell lymphomas. Polycomb proteins have a big role in cell cycle and differentiation. Survivin is another recently recognized player in non-Hodgkin lymphoma.
Objective: To study the pattern of Bmi-1 and Survivin in different categories of B- and T/NK- cell non-Hodgkin lymphomas, their association with the clinicopathological parameters, and their impact on the prognosis of non-Hodgkin lymphomas.
Material& methods: Immunohistochemical staining was used to study paraffin samples of 267 patients’ biopsies. We used tonsils and reactive lymph node as normal control.
Results: Both Bmi-1 and Survivin showed significant upregulation in several subtypes B- (P =.000-.02 for Bmi-1 and.00-.03 for Survivin) and T/NK cell lymphomas (P=.009-.03 for Bmi-1 and 0.008- 0.009 for Survivin) compared to normal tissue. Significant positive correlation between Bmi-1 and Survivin was detected in both B- (Co= 0.539**, P =.00) and T - cell lymphomas (Co= 0.560**, P =.000). A statistically significant difference between overall survival and expression of both BMI-1 and Survivin was detected (P =.00 for BMI-1and survivin).
Conclusion: Bmi-1 and Survivin show significant upregulation as well correlation with clinicopathological parameters and overall survival of non-Hodgkin lymphomas.

Keywords

Polycomb group protein / BMI-1 / Survivin / Non-Hodgkin lymphomas / Prognosis

References

[1] Hendrik N, Bernd D, Georg L. Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol. 2011; 29: 1803-1811. PMid:21483013. https://doi.org/10.1200/JCO.2010.33.3252

[2] Van FJ, Raaphorst FM, Blokzijl T, et al. Cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma Coexpression of BMI-1 and EZH 2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2010.

[3] Hopp L, Nersisyan L, Löffler-wirth H, et al. Epigenetic Hetero-geneity of B-Cell Lymphoma: Chromatin Modifiers. Genes. 2015; 1076-1112. PMid:26506391. https://doi.org/10.3390/genes6041076

[4] Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lym-phoma: a predictive model based on a retrospective analysis of 987 cases. 2011.

[5] Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000; 403: 41-45. PMid:10638745. https://doi.org/10.1038/47412

[6] Vanasse GJ, Concannon P, Willerford DM. Regulated genomic in-stability and neoplasia in the lymphoid lineage. Blood. 1999; 94: 3997-4010.

[7] Warnke RA, Weiss LM, Chan JKC. Malignant lymphomas: an overview. Tumors Lymph Nodes Spleen. 2000; 53-58.

[8] Pirrotta V. Polycomb Silencing and the Maintenance of Stable Chro-matin States, in:Springer, Berlin, Heidelberg, 2013:pp. 205-228. https://doi.org/10.1007/978-3-540-69111-2_10

[9] Sahasrabuddhe AA. BMI1: A Biomarker of Hematologic Malig-nancies, Biomark. Cancer. 2016; 8: BIC. S33376. PMid:27168727. https://doi.org/10.4137/BIC.S33376

[10] Abd KL, Oka T, Takata K, et al. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. Virchows Arch. 2013; 463: 697-711. PMid:23948956. https://doi.org/10.1007/s00428-013-1428-y

[11] Rosenwald A, Brown PO, Weisenburger DD, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature. 2002; 403: 503-511. PMid:10676951. https://doi.org/10.1038/35000501

[12] AlJohani N, Choi SJ, Day AG, et al. Abundant expression of BMI 1 in follicular lymphoma is associated with reduced overall survival, Leuk. Lymphoma. 2018; 59: 2211-2219. PMid:29251058. https://doi.org/10.1080/10428194.2017.1410883

[13] Wang L, Brown JL, Cao R, et al. Hierarchical recruitment of poly-comb group silencing complexes. Mol Cell. 2004; 14: 637-646. PMid:15175158. https://doi.org/10.1016/j.molcel.2004.05.009

[14] Vos JW, Ossenkoppele JC, van Galen PE, et al. Raaphorst, Expres-sion of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol. 2006; 60: 167-172. PMid:16837630. https://doi.org/10.1136/jcp.2006.038752

[15] Raaphorst FM. Deregulated expression of Polycomb-group onco-genes in human malignant lymphomas and epithelial tumors. Hum Mol Genet. 2005; 14: 93-100. PMid:15809278. https://doi.org/10.1093/hmg/ddi111

[16] Wang CG, Ye YJ, Yuan J, et al. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and progno-sis. World J. Gastroenterol. 2010; 16: 2421-2427. PMid:20480530. https://doi.org/10.3748/wjg.v16.i19.2421

[17] Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH 2 (Tyr641) in follicular and diffuse large B-cell lym-phomas of germinal-center origin. Nat Genet. 2010; 42: 181-185. PMid:20081860. https://doi.org/10.1038/ng.518

[18] Bedewy ML, Elgammal MA, Bedewy ML, et al. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin’s lymphoma. Annals of Hematology. 2013; 92: 1359-1367. PMid:23652586. https://doi.org/10.1007/s00277-013-1775-4

[19] Li J, Wu H. Expression of survivin in Human Non-Hodgkin Lym-phoma and Its Correlation with Proliferation and Angiogenesis. Jour-nal of Huazhong University of Science and Technology. 2006; 26:504- 507. https://doi.org/10.1007/s11596-006-0504-9

[20] Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997; 3: 917-921. PMid:9256286. https://doi.org/10.1038/nm0897-917

[21] Zhang Y, Zhou S, Yan H, et al. MiR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1. Sci Rep. 2016; 6: 19995. PMid:26847520. https://doi.org/10.1038/srep19995

[22] Bentley S. WHO Classification of Tumours: Pathology and Ge-netics. Tumours of Haematopoietic and Lymphoid Tissues. 2003. https://doi.org/10.1046/j.1365-2257.2003.00518.x

[23] Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by im-munohistochemistry using a tissue microarray. Blood. 2004; 103:275- 82. PMid:14504078. https://doi.org/10.1182/blood-2003-05-1545

[24] Foda RM. No-cost manual method for preparation of tissue microar-rays having high quality comparable to semiautomated methods. Appl Immunohistochem Mol Morphol. 2013; 21: 271-4.

[25] Shebl AM, Zalata KR, Amin MM, et al. An inexpensive method of small paraffin tissue microarrays using mechanical pencil tips. Diagn Pathol. 2011; 6: 117. PMid:22132713. https://doi.org/10.1186/1746-1596-6-117

[26] Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016; 13: 496-504. PMid:28154782. https://doi.org/10.20892/j.issn.2095-3941.2016.0066

[27] Yussif SM, Soliman N. Assessment of neuroendocrine markers in different molecular subtypes of invasive breast carcinoma and its impact on prognosis. Merit Reasearch Journals. 2018; 6(5):204-214.

[28] Hadzi-Pecova L, Petrusevska G, Stojanovic A. Non-Hodgkin’s lym-phomas: immunologic prognostic studies. Prilozi. 2007; 28: 39-55.

[29] Mazur G, Wróbel T, Urbaniak J, et al. Survivin expression in lymph nodes affected by lymphoma and reactive hyperplasia. Rocz Akad Med Bialymst. 2004; 49: 76-8.

[30] Kondo E, Yoshino T. Expression of apoptosis regulators in germinal centers and germinal center-derived B-cell lymphomas: Insight into B- cell lymphomagenesis. Pathology International. 2007; 391-397. PMid:17587238. https://doi.org/10.1111/j.1440-1827.2007.02115.x

[31] El Bolkainy, Nouh MA. Pathology of Cancer. 4th ed. Cairo Press, Cairo, Egypt, 2013.

[32] He C, Liu Z, Ji J, et al. Prognostic value of survivin in patients with non-hodgkin’s lymphoma: A meta-analysis. Int J Clin Exp Med. 2015; 8(4):5847-54.

[33] Bhattacharyya J, Mihara K, Ohtsubo M, et al. Kimura, Overexpres-sion of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression. Cancer Sci. 2012; 103: 34-41. PMid:21999765. https://doi.org/10.1111/j.1349-7006.2011.02121.x

[34] Avramović V, Petrović V, Jović M, et al. Quantification of cells ex-pressing markers of proliferation and apoptosis in chronic tonsilitis. Acta Otorhinolaryngol Ital. 2015; 35(4):277-84.

[35] Acquati S, Greco A, Licastro D, et al. Epigenetic regulation of sur-vivin by Bmi1 is cell type specific during corticogenesis and in gliomas. Stem Cells. 2013; 31: 190-202. PMid:23132836. https://doi.org/10.1002/stem.1274